Edwards Lifesciences Co. (NYSE:EW) Shares Sold by 180 Wealth Advisors LLC

180 Wealth Advisors LLC cut its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 11.0% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 10,276 shares of the medical research company’s stock after selling 1,269 shares during the period. 180 Wealth Advisors LLC’s holdings in Edwards Lifesciences were worth $940,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in EW. Castleview Partners LLC bought a new stake in shares of Edwards Lifesciences during the first quarter valued at about $25,000. Core Alternative Capital lifted its stake in shares of Edwards Lifesciences by 96.1% in the 1st quarter. Core Alternative Capital now owns 353 shares of the medical research company’s stock worth $29,000 after acquiring an additional 173 shares during the period. Jones Financial Companies Lllp bought a new position in shares of Edwards Lifesciences in the first quarter valued at approximately $33,000. MCF Advisors LLC raised its holdings in Edwards Lifesciences by 179.6% during the first quarter. MCF Advisors LLC now owns 411 shares of the medical research company’s stock worth $34,000 after purchasing an additional 264 shares in the last quarter. Finally, Compass Wealth Management LLC bought a new position in Edwards Lifesciences during the 4th quarter valued at $31,000. 79.25% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

EW has been the subject of several research analyst reports. Mizuho upped their price objective on Edwards Lifesciences from $95.00 to $102.00 in a report on Monday, July 17th. 58.com reiterated a “reiterates” rating on shares of Edwards Lifesciences in a report on Tuesday, June 27th. Robert W. Baird started coverage on shares of Edwards Lifesciences in a report on Tuesday, July 18th. They set an “outperform” rating and a $107.00 target price for the company. Piper Sandler dropped their price target on Edwards Lifesciences from $88.00 to $83.00 and set a “neutral” rating on the stock in a report on Friday, September 8th. Finally, TheStreet lowered Edwards Lifesciences from a “b-” rating to a “c+” rating in a research note on Wednesday, August 9th. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $92.42.

Edwards Lifesciences Price Performance

NYSE EW opened at $72.94 on Tuesday. The company has a 50 day moving average price of $81.38 and a two-hundred day moving average price of $83.98. Edwards Lifesciences Co. has a 12-month low of $67.13 and a 12-month high of $94.87. The stock has a market capitalization of $44.34 billion, a PE ratio of 32.27, a price-to-earnings-growth ratio of 3.95 and a beta of 1.03. The company has a quick ratio of 2.30, a current ratio of 3.15 and a debt-to-equity ratio of 0.09.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Wednesday, July 26th. The medical research company reported $0.66 earnings per share for the quarter, topping analysts’ consensus estimates of $0.65 by $0.01. Edwards Lifesciences had a return on equity of 25.43% and a net margin of 24.56%. The company had revenue of $1.53 billion during the quarter, compared to analysts’ expectations of $1.51 billion. During the same quarter in the previous year, the firm earned $0.63 earnings per share. The business’s quarterly revenue was up 11.4% compared to the same quarter last year. As a group, equities analysts predict that Edwards Lifesciences Co. will post 2.55 earnings per share for the current fiscal year.

Insider Activity

In related news, VP Donald E. Bobo, Jr. sold 4,500 shares of the firm’s stock in a transaction on Thursday, September 14th. The shares were sold at an average price of $73.71, for a total value of $331,695.00. Following the transaction, the vice president now directly owns 39,503 shares in the company, valued at approximately $2,911,766.13. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 4,500 shares of the firm’s stock in a transaction that occurred on Thursday, September 14th. The stock was sold at an average price of $73.71, for a total value of $331,695.00. Following the sale, the vice president now owns 39,503 shares of the company’s stock, valued at approximately $2,911,766.13. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Larry L. Wood sold 8,660 shares of the company’s stock in a transaction that occurred on Thursday, September 14th. The stock was sold at an average price of $73.63, for a total value of $637,635.80. Following the transaction, the insider now owns 213,794 shares of the company’s stock, valued at $15,741,652.22. The disclosure for this sale can be found here. Insiders have sold a total of 174,359 shares of company stock valued at $14,301,522 over the last 90 days. 1.29% of the stock is currently owned by company insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.